Home  
Mechanism of Action [MOA] Classes (329)

• 5-Lipoxygenase Inhibitors [MoA]
• 5-alpha Reductase Inhibitors [MoA]
• AMPA Receptor Antagonists [MoA]
• Acetyl Aldehyde Dehydrogenase Inhibitors [MoA]
• Acetylcholine Release Inhibitors [MoA]
• Acidifying Activity [MoA]
• Adenosine Receptor Agonists [MoA]
• Adenosine Triphosphate-Citrate Lyase Inhibitors [MoA]
• Adrenal Steroid Synthesis Inhibitors [MoA]
• Adrenergic alpha-Agonists [MoA]
• Adrenergic alpha-Antagonists [MoA]
• Adrenergic alpha1-Agonists [MoA]
• Adrenergic alpha2-Agonists [MoA]
• Adrenergic beta-Agonists [MoA]
• Adrenergic beta-Antagonists [MoA]
• Adrenergic beta1-Antagonists [MoA]
• Adrenergic beta2-Agonists [MoA]
• Adrenergic beta2-Antagonists [MoA]
• Adrenergic beta3-Agonists [MoA]
• Aldosterone Antagonists [MoA]
• Alkylating Activity [MoA]
• Ammonium Ion Binding Activity [MoA]
• Amyloid Beta-directed Antibody Interactions [MoA]
• Androgen Receptor Agonists [MoA]
• Androgen Receptor Antagonists [MoA]
• Angiopoietin-like 3 Inhibitors [MoA]
• Angiotensin 2 Receptor Antagonists [MoA]
• Angiotensin 2 Type 1 Receptor Antagonists [MoA]
• Angiotensin-converting Enzyme Inhibitors [MoA]
• Anthrax Protective Antigen-directed Antibody Interactions [MoA]
• Antibody-Surface Protein Interactions [MoA]
• Antigen Neutralization [MoA]
• Aromatase Inhibitors [MoA]
• Aryl Hydrocarbon Receptor Agonists [MoA]
• B Lymphocyte Stimulator-directed Antibody Interactions [MoA]
• Bacterial Neurotoxin Neutralization [MoA]
• Bcr-Abl Tyrosine Kinase Inhibitors [MoA]
• Bile Salt Export Pump Inhibitors [MoA]
• Bile-acid Binding Activity [MoA]
• Breast Cancer Resistance Protein Inhibitors [MoA]
• Bruton's Tyrosine Kinase Inhibitors [MoA]
• CD123 Interactions [MoA]
• CD19 Receptor Interactions [MoA]
• CD19-directed Antibody Interactions [MoA]
• CD20-directed Antibody Interactions [MoA]
• CD22-directed Antibody Interactions [MoA]
• CD3 Receptor Agonists [MoA]
• CD3-directed Antibody Interactions [MoA]
• CD30-directed Antibody Interactions [MoA]
• CD33-directed Antibody Interactions [MoA]
• CD38-directed Antibody Interactions [MoA]
• CD4-directed Antibody Interactions [MoA]
• CD52-directed Antibody Interactions [MoA]
• CD80-directed Antibody Interactions [MoA]
• CD86-directed Antibody Interactions [MoA]
• CTLA-4-directed Antibody Interactions [MoA]
• CXC Chemokine Receptor 4 Antagonists [MoA]
• Calcineurin Inhibitors [MoA]
• Calcitonin Gene-related Peptide Antagonists [MoA]
• Calcitonin Gene-related Peptide Receptor Antagonists [MoA]
• Calcium Channel Antagonists [MoA]
• Calcium Chelating Activity [MoA]
• Carbamoyl Phosphate Synthetase 1 Activators [MoA]
• Carbonic Anhydrase Inhibitors [MoA]
• Cardiac Myosin Inhibitors [MoA]
• Catechol O-Methyltransferase Inhibitors [MoA]
• Catecholamine Synthesis Inhibitors [MoA]
• Chelating Activity [MoA]
• Chemokine Co-receptor 5 Antagonists [MoA]
• Chemokine Receptor Type 4 Interactions [MoA]
• Chloride Channel Activation Potentiators [MoA]
• Chloride Channel Activators [MoA]
• Cholinergic Antagonists [MoA]
• Cholinergic Muscarinic Agonists [MoA]
• Cholinergic Muscarinic Antagonists [MoA]
• Cholinesterase Inhibitors [MoA]
• Classical Complement Pathway Inhibitors [MoA]
• Claudin 18.2-directed Antibody Interactions [MoA]
• Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors [MoA]
• Competitive Opioid Antagonists [MoA]
• Complement 5a Receptor Antagonists [MoA]
• Complement C5 Inhibitors [MoA]
• Complement Factor D Inhibitors [MoA]
• Complement Inhibitors [MoA]
• Corticosteroid Hormone Receptor Agonists [MoA]
• Corticotropin-releasing Factor Type 1 Receptor Antagonists [MoA]
• Cyclooxygenase Inhibitors [MoA]
• Cystine Disulfide Reduction [MoA]
• Cytochrome P450 11A1 Inhibitors [MoA]
• Cytochrome P450 11B1 Inhibitors [MoA]
• Cytochrome P450 17A1 Inhibitors [MoA]
• Cytochrome P450 1A Inducers [MoA]
• Cytochrome P450 1A2 Inducers [MoA]
• Cytochrome P450 1A2 Inhibitors [MoA]
• Cytochrome P450 2A6 Inhibitors [MoA]
• Cytochrome P450 2B6 Inducers [MoA]
• Cytochrome P450 2B6 Inhibitors [MoA]
• Cytochrome P450 2C19 Inducers [MoA]
• Cytochrome P450 2C19 Inhibitors [MoA]
• Cytochrome P450 2C8 Inducers [MoA]
• Cytochrome P450 2C8 Inhibitors [MoA]
• Cytochrome P450 2C9 Inducers [MoA]
• Cytochrome P450 2C9 Inhibitors [MoA]
• Cytochrome P450 2D6 Inducers [MoA]
• Cytochrome P450 2D6 Inhibitors [MoA]
• Cytochrome P450 2E1 Inducers [MoA]
• Cytochrome P450 3A Inducers [MoA]
• Cytochrome P450 3A Inhibitors [MoA]
• Cytochrome P450 3A4 Inducers [MoA]
• Cytochrome P450 3A4 Inhibitors [MoA]
• Cytochrome P450 3A5 Inhibitors [MoA]
• Cytochrome P450 Inhibitors [MoA]
• Cytomegalovirus pUL97 Kinase Inhibitors [MoA]
• DNA Polymerase Inhibitors [MoA]
• DNA Terminase Complex Inhibitors [MoA]
• DOPA Decarboxylase Inhibitors [MoA]
• Dihydrofolate Reductase Inhibitors [MoA]
• Dihydroorotate Dehydrogenase Inhibitors [MoA]
• Dipeptidase Inhibitors [MoA]
• Dipeptidyl Peptidase 4 Inhibitors [MoA]
• Dopamine Agonists [MoA]
• Dopamine D2 Antagonists [MoA]
• Dopamine Uptake Inhibitors [MoA]
• Dyes [MoA]
• Endothelin Receptor Antagonists [MoA]
• Enzyme Stabilizers [MoA]
• Epoxide Hydrolase Inhibitors [MoA]
• Estrogen Receptor Agonists [MoA]
• Estrogen Receptor Antagonists [MoA]
• Factor Xa Inhibitors [MoA]
• Farnesoid X Receptor Agonists [MoA]
• Farnesyltransferase Inhibitors [MoA]
• Fibroblast Growth Factor Receptor Inhibitors [MoA]
• Folic Acid Metabolism Inhibitors [MoA]
• Full Opioid Agonists [MoA]
• Fusion Protein Inhibitors [MoA]
• G-Protein-linked Receptor Interactions [MoA]
• GABA A Agonists [MoA]
• GABA A Receptor Positive Modulators [MoA]
• GABA B Agonists [MoA]
• Gamma Secretase Inhibitors [MoA]
• Glucagon Receptor Agonists [MoA]
• Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
• Glucagon-like Peptide-2 (GLP-2) Agonists [MoA]
• Glucosylceramide Synthase Inhibitors [MoA]
• Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]
• Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions [MoA]
• Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
• Growth Hormone Secretagogue Receptor Agonists [MoA]
• Guanylate Cyclase Activators [MoA]
• Guanylate Cyclase Stimulators [MoA]
• HCV NS3/4A Protease Inhibitors [MoA]
• HER1 Antagonists [MoA]
• HER2-directed Antibody Interactions [MoA]
• HER2/Neu/cerbB2 Antagonists [MoA]
• HIV 1 Post-attachment Fusion Inhibitors [MoA]
• HIV Integrase Inhibitors [MoA]
• HIV Protease Inhibitors [MoA]
• Hemoglobin S Polymerization Inhibitors [MoA]
• Histamine H1 Receptor Antagonists [MoA]
• Histamine H2 Receptor Antagonists [MoA]
• Histone Deacetylase Inhibitors [MoA]
• Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
• Hydroxyphenylpyruvate Dioxygenase Inhibitors [MoA]
• Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
• Hypoxia-inducible Factor 2 alpha Inhibitors [MoA]
• IgE-directed Antibody Interactions [MoA]
• Ileal Bile Acid Transporter Inhibitors [MoA]
• Insulin-like Growth Factor-1 Receptor Inhibitors [MoA]
• Integrin Receptor Antagonists [MoA]
• Interferon Inducers [MoA]
• Interferon gamma Antagonists [MoA]
• Interleukin 1 Receptor Antagonists [MoA]
• Interleukin 17 Receptor A Antagonists [MoA]
• Interleukin 2 Receptor Antagonists [MoA]
• Interleukin 2 Receptor-directed Antibody Interactions [MoA]
• Interleukin 4 Receptor alpha Antagonists [MoA]
• Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]
• Interleukin 6 Receptor Antagonists [MoA]
• Interleukin-12 Antagonists [MoA]
• Interleukin-13 Antagonists [MoA]
• Interleukin-17A Antagonists [MoA]
• Interleukin-23 Antagonists [MoA]
• Interleukin-31 Receptor alpha Antagonists [MoA]
• Interleukin-36 Receptor Antagonists [MoA]
• Interleukin-5 Antagonists [MoA]
• Interleukin-6 Antagonists [MoA]
• Ion Exchange Activity [MoA]
• Iron Chelating Activity [MoA]
• Irrigation [MoA]
• Isocitrate Dehydrogenase 1 Inhibitors [MoA]
• Isocitrate Dehydrogenase 2 Inhibitors [MoA]
• Janus Kinase Inhibitors [MoA]
• Kallikrein Inhibitors [MoA]
• Kinase Inhibitors [MoA]
• Lead Chelating Activity [MoA]
• Leukotriene Receptor Antagonists [MoA]
• Lipase Inhibitors [MoA]
• Lymphocyte Activation Gene-3 Antagonists [MoA]
• Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]
• M2 Protein Inhibitors [MoA]
• Magnesium Ion Exchange Activity [MoA]
• Magnetic Resonance Contrast Activity [MoA]
• Melanin Synthesis Inhibitors [MoA]
• Melanocortin 4 Receptor Agonists [MoA]
• Melatonin Receptor Agonists [MoA]
• Methylating Activity [MoA]
• Mineralocorticoid Receptor Antagonists [MoA]
• Mitogen-Activated Protein Kinase Kinase 1 Inhibitors [MoA]
• Mitogen-Activated Protein Kinase Kinase 2 Inhibitors [MoA]
• Monoamine Oxidase Inhibitors [MoA]
• Monoamine Oxidase-B Inhibitors [MoA]
• Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]
• Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA]
• Neonatal Fc Receptor Blockers [MoA]
• Neuraminidase Inhibitors [MoA]
• Neurokinin 1 Antagonists [MoA]
• Neurokinin 3 Receptor Antagonists [MoA]
• Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
• Norepinephrine Uptake Inhibitors [MoA]
• Nuclear Export Inhibitors [MoA]
• Nucleic Acid Synthesis Inhibitors [MoA]
• Nucleoside Reverse Transcriptase Inhibitors [MoA]
• Opioid Antagonists [MoA]
• Opioid mu-Receptor Agonists [MoA]
• Orexin Receptor Antagonists [MoA]
• Organic Anion Transporter 1 Inhibitors [MoA]
• Organic Anion Transporter 3 Inhibitors [MoA]
• Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
• Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
• Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]
• Organic Cation Transporter 1 Inhibitors [MoA]
• Organic Cation Transporter 2 Inhibitors [MoA]
• Osmotic Activity [MoA]
• P-Glycoprotein Inducers [MoA]
• P-Glycoprotein Inhibitors [MoA]
• P-Selectin Blockers [MoA]
• P2Y12 Receptor Antagonists [MoA]
• PCSK9 Inhibitors [MoA]
• Partial Opioid Agonists [MoA]
• Peroxisome Proliferator-activated Receptor Agonists [MoA]
• Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]
• Peroxisome Proliferator-activated Receptor gamma Agonists [MoA]
• Phosphate Chelating Activity [MoA]
• Phosphodiesterase 3 Inhibitors [MoA]
• Phosphodiesterase 4 Inhibitors [MoA]
• Phosphodiesterase 5 Inhibitors [MoA]
• Phosphoinositide 3-Kinase alpha Inhibitors [MoA]
• Photoabsorption [MoA]
• Platelet-derived Growth Factor alpha Receptor Inhibitors [MoA]
• Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
• Positron Emitting Activity [MoA]
• Potassium Channel Antagonists [MoA]
• Potassium Ion Binding Activity [MoA]
• Potassium Ion Exchange Activity [MoA]
• Progestational Hormone Receptor Antagonists [MoA]
• Programmed Death Ligand-1 Antagonists [MoA]
• Programmed Death Ligand-1-directed Antibody Interactions [MoA]
• Programmed Death Receptor-1-directed Antibody Interactions [MoA]
• Prostacyclin Receptor Agonists [MoA]
• Prostaglandin Receptor Agonists [MoA]
• Proteasome Inhibitors [MoA]
• Protein Kinase Inhibitors [MoA]
• Protein Synthesis Inhibitors [MoA]
• Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors [MoA]
• Proton Pump Inhibitors [MoA]
• Pyruvate Kinase Activators [MoA]
• RANK Ligand Blocking Activity [MoA]
• RNA Replicase Inhibitors [MoA]
• RNA Synthetase Inhibitors [MoA]
• Radioligand Activity [MoA]
• Radiopharmaceutical Activity [MoA]
• Rearranged during Transfection (RET) Inhibitors [MoA]
• Receptor Tyrosine Kinase Inhibitors [MoA]
• Reduction Activity [MoA]
• SLAMF7-directed Antibody Interactions [MoA]
• Sclerosing Activity [MoA]
• Selective Estrogen Receptor Modulators [MoA]
• Serotonin 1b Receptor Agonists [MoA]
• Serotonin 1d Receptor Agonists [MoA]
• Serotonin 3 Receptor Antagonists [MoA]
• Serotonin 4 Receptor Agonists [MoA]
• Serotonin Uptake Inhibitors [MoA]
• Sigma-1 Receptor Agonists [MoA]
• Smoothened Receptor Antagonists [MoA]
• Sodium Channel Antagonists [MoA]
• Sodium-Glucose Transporter 2 Inhibitors [MoA]
• Somatostatin Receptor Agonists [MoA]
• Sphingosine 1-Phosphate Receptor Modulators [MoA]
• Stem Cell Factor (KIT) Receptor Inhibitors [MoA]
• Surfactant Activity [MoA]
• Survival of Motor Neuron 2 Splicing Modifiers [MoA]
• Thrombin Inhibitors [MoA]
• Thrombopoietin Receptor Agonists [MoA]
• Thymic Stromal Lymphopoietin Blockers [MoA]
• Thyroid Hormone Receptor beta Agonists [MoA]
• Thyroid Hormone Synthesis Inhibitors [MoA]
• Tissue Factor Pathway Inhibitor Antagonists [MoA]
• Topoisomerase Inhibitors [MoA]
• Tropomyosin Receptor Kinases Inhibitors [MoA]
• Tropomyosin Receptor Tyrosine Kinase A Inhibitors [MoA]
• Tropomyosin Receptor Tyrosine Kinase B Inhibitors [MoA]
• Tropomyosin Receptor Tyrosine Kinase C Inhibitors [MoA]
• Tumor Necrosis Factor Receptor Blocking Activity [MoA]
• Type I Interferon Receptor Antagonists [MoA]
• Type II RAF Kinase Inhibitors [MoA]
• Tyrosine Kinase 2 Inhibitors [MoA]
• Tyrosine Kinase Inhibitors [MoA]
• UDP Glucuronosyltransferases Inducers [MoA]
• UGT1A1 Inducers [MoA]
• UGT1A1 Inhibitors [MoA]
• UGT1A9 Inhibitors [MoA]
• UGT2B7 Inhibitors [MoA]
• Ultrasound Contrast Activity [MoA]
• Uncompetitive NMDA Receptor Antagonists [MoA]
• Urease Inhibitors [MoA]
• VEGFR2 Inhibitors [MoA]
• Vascular Endothelial Growth Factor Inhibitors [MoA]
• Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
• Vasopressin Receptor Agonists [MoA]
• Vasopressin V2 Receptor Antagonists [MoA]
• Vesicular Monoamine Transporter 2 Inhibitors [MoA]
• Virus Neutralization [MoA]
• X-Ray Contrast Activity [MoA]
• Xanthine Oxidase Inhibitors [MoA]
• Zaire Ebolavirus Glycoprotein-directed Antibody Interactions [MoA]
• alpha Glucosidase Inhibitors [MoA]
• beta Lactamase Inhibitors [MoA]
• mTOR Inhibitors [MoA]

Click on a **Mechanism of Action (MOA) Class Name** on the left to load the corresponding drugs.